These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 37828817)

  • 41. Acute toxicity and health-related quality of life outcomes of localized prostate cancer patients treated with magnetic resonance imaging-guided high-dose-rate brachytherapy: A prospective phase II trial.
    Sanmamed N; Adleman J; Berlin A; Borg J; Lao B; Weersink R; Simeonov A; Rink A; Beiki-Ardakani A; Menard C; Chung P; Helou J
    Brachytherapy; 2023; 22(1):58-65. PubMed ID: 36414526
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of Physician-recorded Toxicities and Patient-reported Outcomes of Five Different Radiotherapy Methods for Prostate Cancer.
    Ito M; Sasamura K; Takase Y; Kotsuma T; Oshima Y; Minami Y; Suzuki J; Tanaka E; Ohashi W; Oguchi M; Okuda T; Suzuki K; Yoshioka Y
    Anticancer Res; 2021 May; 41(5):2523-2531. PubMed ID: 33952480
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Time Course and Accumulated Risk of Severe Urinary Adverse Events After High- Versus Low-Dose-Rate Prostate Brachytherapy With or Without External Beam Radiation Therapy.
    Tward JD; Jarosek S; Chu H; Thorpe C; Shrieve DC; Elliott S
    Int J Radiat Oncol Biol Phys; 2016 Aug; 95(5):1443-1453. PubMed ID: 27325475
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Low dose rate brachytherapy (LDR-BT) as monotherapy for early stage prostate cancer in Italy: practice and outcome analysis in a series of 2237 patients from 11 institutions.
    Fellin G; Mirri MA; Santoro L; Jereczek-Fossa BA; Divan C; Mussari S; Ziglio F; La Face B; Barbera F; Buglione M; Bandera L; Ghedi B; Di Muzio NG; Losa A; Mangili P; Nava L; Chiarlone R; Ciscognetti N; Gastaldi E; Cattani F; Spoto R; Vavassori A; Giglioli FR; Guarneri A; Cerboneschi V; Mignogna M; Paoluzzi M; Ravaglia V; Chiumento C; Clemente S; Fusco V; Santini R; Stefanacci M; Mangiacotti FP; Martini M; Palloni T; Schinaia G; Lazzari G; Silvano G; Magrini S; Ricardi U; Santoni R; Orecchia R
    Br J Radiol; 2016 Sep; 89(1065):20150981. PubMed ID: 27384381
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparative dosimetrical analysis of intensity-modulated arc therapy, CyberKnife therapy and image-guided interstitial HDR and LDR brachytherapy of low risk prostate cancer.
    Fröhlich G; Ágoston P; Jorgo K; Stelczer G; Polgár C; Major T
    Rep Pract Oncol Radiother; 2021; 26(2):196-202. PubMed ID: 34211769
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Toxicity and clinical outcomes of single-fraction high-dose-rate brachytherapy combined with external beam radiotherapy for high-/very high-risk prostate cancer: A dosimetric analysis of toxicity.
    Sakurai T; Takamatsu S; Shibata S; Iwata K; Taka M; Gabata T; Kumano T; Makino T; Mizokami A
    Jpn J Radiol; 2020 Dec; 38(12):1197-1208. PubMed ID: 32737768
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Biochemical Control and Toxicity Outcomes of Stereotactic Body Radiation Therapy Versus Low-Dose-Rate Brachytherapy in the Treatment of Low- and Intermediate-Risk Prostate Cancer.
    Gogineni E; Rana Z; Soberman D; Sidiqi B; D'Andrea V; Lee L; Potters L; Parashar B
    Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1232-1242. PubMed ID: 33171199
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Impact of post-implant dosimetric parameters on the quality of life of patients treated with low-dose rate brachytherapy for localised prostate cancer: results of a single-institution study.
    Veccia A; Caffo O; Fellin G; Mussari S; Ziglio F; Maines F; Tomio L; Galligioni E
    Radiat Oncol; 2015 Jun; 10():130. PubMed ID: 26054532
    [TBL] [Abstract][Full Text] [Related]  

  • 49. External beam radiotherapy of prostate cancer with or without high dose-rate brachytherapy: the Norwegian experience with long-term urinary and bowel adverse effects.
    Wedde TB; Smaastuen MC; Vatne K; Schulz-Jaavall MB; Fosså SD; Lilleby WL
    Scand J Urol; 2023 Aug; 58():68-75. PubMed ID: 37644904
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Stereotactic pelvic radiotherapy with HDR boost for dose escalation in intermediate and high-risk prostate cancer (SPARE): Efficacy, toxicity and quality of life.
    Musunuru HB; Cheung P; Vesprini D; Liu SK; Chu W; Chung HT; Morton G; Deabreu A; Davidson M; Ravi A; Helou J; Ho L; Zhang L; Loblaw A
    Radiother Oncol; 2021 Aug; 161():40-46. PubMed ID: 34089752
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Salvage brachytherapy for recurrent prostate cancer after definitive radiation therapy: A comparison of low-dose-rate and high-dose-rate brachytherapy and the importance of prostate-specific antigen doubling time.
    Kollmeier MA; McBride S; Taggar A; Anderson E; Lin M; Pei X; Weiji S; Voros L; Cohen G; Yamada Y; Zelefsky MJ
    Brachytherapy; 2017; 16(6):1091-1098. PubMed ID: 28838648
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Patient-reported health-related quality of life outcomes after HDR brachytherapy between small (<60 cc) and large (≥60 cc) prostate glands.
    Press RH; Morgan TM; Cutrell PK; Zhang C; Chen Z; Rahnema S; Sanda M; Pattaras J; Patel P; Jani AB; Rossi PJ
    Brachytherapy; 2019; 18(1):13-21. PubMed ID: 30262410
    [TBL] [Abstract][Full Text] [Related]  

  • 53. PSA outcomes and late toxicity of single-fraction HDR brachytherapy and LDR brachytherapy as monotherapy in localized prostate cancer: A phase 2 randomized pilot study.
    Reynaud T; Hathout L; Carignan D; Barkati M; Martin AG; Foster W; Lacroix F; Delouya G; Taussky D; Morton G; Vigneault E
    Brachytherapy; 2021; 20(6):1090-1098. PubMed ID: 34238688
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Long-term outcomes analysis of low-dose-rate brachytherapy in clinically T3 high-risk prostate cancer.
    Agarwal M; Chhabra AM; Amin N; Braccioforte MH; Molitoris JK; Moran BJ
    Brachytherapy; 2018; 17(6):882-887. PubMed ID: 30143400
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Long-term oncologic outcomes of low dose-rate brachytherapy compared to hypofractionated external beam radiotherapy for intermediate -risk prostate cancer.
    Sanmamed N; Joseph L; Crook J; Craig T; Warde P; Tomasso AD; Chung P; Berlin A; Bayley A; Saibishkumar EP; Glicksman R; Raman S; Catton C; Helou J
    Brachytherapy; 2023; 22(2):188-194. PubMed ID: 36549968
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Quality of life after brachytherapy or robot-assisted radical prostatectomy for localized prostate cancer].
    Martín-López JE; Rodríguez-López R; Romero-Tabares A; Beltran-Calvo C; Molina-López T; Baena-González V
    Arch Esp Urol; 2015 Mar; 68(2):142-51. PubMed ID: 25774821
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Dose to the dominant intraprostatic lesion using HDR vs. LDR monotherapy: A Phase II randomized trial.
    Tissaverasinghe S; Crook J; Bachand F; Batchelar D; Hilts M; Araujo C; Anderson D; Bainbridge T; Farnquist B
    Brachytherapy; 2019; 18(3):299-305. PubMed ID: 30795889
    [TBL] [Abstract][Full Text] [Related]  

  • 58. High dose rate brachytherapy boost for prostate cancer: a systematic review.
    Zaorsky NG; Doyle LA; Yamoah K; Andrel JA; Trabulsi EJ; Hurwitz MD; Dicker AP; Den RB
    Cancer Treat Rev; 2014 Apr; 40(3):414-25. PubMed ID: 24231548
    [TBL] [Abstract][Full Text] [Related]  

  • 59. From low-dose-rate to high-dose-rate brachytherapy in lip carcinoma: Equivalent results but fewer complications.
    Guinot JL; Arribas L; Tortajada MI; Crispín V; Carrascosa M; Santos M; Mut A; Vendrell JB; Pesudo C; Chust ML
    Brachytherapy; 2013; 12(6):528-34. PubMed ID: 23850275
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparison of Image-Guided Intensity-Modulated Radiotherapy and Low-dose Rate Brachytherapy with or without External Beam Radiotherapy in Patients with Localized Prostate Cancer.
    Tsubokura T; Yamazaki H; Masui K; Sasaki N; Shimizu D; Suzuki G; Nakamura S; Yamada K; Okihara K; Shiraishi T; Yoshida K; Nishikawa T; Okabe H
    Sci Rep; 2018 Jul; 8(1):10538. PubMed ID: 30002393
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.